Latanoprost/QLS 111 - Qlaris Bio
Alternative Names: QLS-111-FDC; QLS-111-LatanoprostLatest Information Update: 04 Jul 2025
At a glance
- Originator Qlaris Bio
- Class Antiglaucomas; Eye disorder therapies; Prostaglandins; Small molecules
- Mechanism of Action KATP channel modulators; Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ocular hypertension; Open-angle glaucoma
- Preclinical Low tension glaucoma
Most Recent Events
- 11 Jun 2025 Preclinical trials in Low tension glaucoma in USA (Ophthalmic)
- 05 Feb 2025 Efficacy and adverse events data from the phase-II Apteryx trial in Open-angle glaucoma and Ocular hypertension released by Qlaris Bio
- 20 Dec 2024 Qlaris Bio completes the phase II Apteryx trial in Open-angle glaucoma and Ocular hypertension (Combination therapy, In adolescents, In adults, In the elderly) in USA (Ophthalmic) (NCT06249152)